Humaira Ilyas, MS-PhD
@humaira2204.bsky.social
Research Fellow in the Dept. of Biochemistry, Working with Histone Chaperones @einsteinmed. Cancer Biologist, NMR Spectroscopy, Science Communication.
Book Lover, & Webseries Buff outside of lab.
Book Lover, & Webseries Buff outside of lab.
Pinned
Hi @bsky.app, I’m Humaira, a molecular biologist and protein scientist passionate about decoding complex biological systems and translating that knowledge into therapeutic insights.
Hi @bsky.app, I’m Humaira, a molecular biologist and protein scientist passionate about decoding complex biological systems and translating that knowledge into therapeutic insights.
June 23, 2025 at 9:21 PM
Hi @bsky.app, I’m Humaira, a molecular biologist and protein scientist passionate about decoding complex biological systems and translating that knowledge into therapeutic insights.
Reposted by Humaira Ilyas, MS-PhD
We discovered a new AML vulnerability:
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia
NPM1-mutated acute myeloid leukemia (AML) is defined by aberrant cytoplasmic localization of the mutant NPM1c protein, and therapeutic strategies targeting this specific disease remain limited. Here, ...
bit.ly
April 10, 2025 at 2:35 PM
We discovered a new AML vulnerability:
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
TTLL4 glutamylates NPM1c and helps leukemia cells thrive.
Knock it down and cells differentiate and survival improves.
Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
Reposted by Humaira Ilyas, MS-PhD
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia https://www.biorxiv.org/content/10.1101/2025.04.07.647605v1
April 10, 2025 at 2:48 AM
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia https://www.biorxiv.org/content/10.1101/2025.04.07.647605v1
Reposted by Humaira Ilyas, MS-PhD
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia https://www.biorxiv.org/content/10.1101/2025.04.07.647605v1
April 10, 2025 at 2:48 AM
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia https://www.biorxiv.org/content/10.1101/2025.04.07.647605v1